Alnylam is hoping to file a second RNA interference (RNAi) drug with the FDA by the end of 2018 after unveiling encouraging early-stage data for givosiran in a rare liver disease.<
Constellation Pharmaceuticals, a company focused on developing small molecule therapies for difficult-to-treat cancers has raised $100 million from a group of old and new investors.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
